By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Lightlake Therapeutics Inc. 



London      United Kingdom
Phone: n/a Fax:


SEARCH JOBS








Company News
Lightlake Therapeutics Inc. (LLTP) Announces Adapt Pharma Limited Submits NDA To FDA For Narcan (naloxone) Nasal Spray 7/30/2015 10:38:04 AM
Lightlake Therapeutics Inc. (LLTP) Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 6/3/2015 9:57:21 AM
Lightlake Therapeutics Inc. (LLTP) Announces Adapt Pharma Limited Successfully Completed Intranasal Naloxone Study 4/22/2015 11:31:18 AM
Lightlake Therapeutics Inc. (LLTP) March 5th Presentation At VirtualInvestorConferences.com Now Available For On-Demand Viewing 3/9/2015 10:35:19 AM
Lightlake Therapeutics Inc. (LLTP), Licensor Of A Treatment To Reverse Opioid Overdoses, To Webcast Live, At VirtualInvestorConferences.com March 5th 2/27/2015 10:32:03 AM
Lightlake Therapeutics Inc. (LLTP) Announces Fast Track Designation From The United States FDA For Intranasal Naloxone Treatment To Reverse Opioid Overdose 2/17/2015 11:47:12 AM
Lightlake Therapeutics Inc. (LLTP) Announces Arvind Agrawal Appointed Executive Vice President, Medical Affairs 2/9/2015 10:06:28 AM
Lightlake Therapeutics Inc. (LLTP), Adapt Pharma Forge Deal Worth $55 Million 12/16/2014 9:17:03 AM
Lightlake Therapeutics Inc. (LLTP) Commences Trial For Treatment Of Opioid Overdose With The U.S. National Institute On Drug Abuse (NIDA) 12/4/2014 11:04:21 AM
Lightlake Therapeutics Inc. (LLTP) Announces Closing Of Investments In Two Products 10/2/2014 9:19:22 AM
1234
//-->